Aitia
Founded Year
2000Stage
Corporate Minority | AliveTotal Raised
$65.25MMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-13 points in the past 30 days
About Aitia
Aitia focuses on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. It is used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Loading...
Aitia's Product Videos
ESPs containing Aitia
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI-derived small molecule drugs market leverages AI and machine learning to discover and develop novel small molecule therapeutics. Companies in this market combine physics-based AI algorithms, deep learning models, and generative AI with experimental validation to enable target identification, virtual screening, and lead optimization. Proprietary platforms integrate computational approaches w…
Aitia named as Outperformer among 15 other companies, including Insilico Medicine, Recursion, and Schrodinger.
Aitia's Products & Differentiators
Gemini Digital Twin
Gemini Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across “digital twins cohorts” to discover and validate novel drug targets. Gemini Digital Twins also enable the simulation of disease progression and drug response at the individual patient level across “digital twins cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.
Loading...
Research containing Aitia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aitia in 2 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market map
Expert Collections containing Aitia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aitia is included in 7 Expert Collections, including Digital Health 50.
Digital Health 50
150 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,329 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Oncology Tech
463 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Artificial Intelligence
7,222 items
Latest Aitia News
Feb 22, 2025
Recent advancements highlight its role in drug discovery, treatment monitoring, and neurotoxicity detection. NfL levels can indicate axonal health and disease progression across various research stages, from laboratory studies to clinical trials. Elevated NfL levels in cerebrospinal fluid and plasma correlate with neurodegenerative diseases, aiding in diagnosis and treatment response evaluation. Artificial intelligence is enhancing biomarker selection by analyzing large datasets to identify new targets. Collaborations, like that between Charles River Laboratories and Aitia, aim to improve the efficiency of biomarker discovery in drug development. With a significance score of , this news ranks in the top of today's analyzed articles Get summaries of news with significance over (usually ~10 stories per week). Read by 8000 minimalists.
Aitia Frequently Asked Questions (FAQ)
When was Aitia founded?
Aitia was founded in 2000.
Where is Aitia's headquarters?
Aitia's headquarters is located at 561 Windsor St., Cambridge.
What is Aitia's latest funding round?
Aitia's latest funding round is Corporate Minority.
How much did Aitia raise?
Aitia raised a total of $65.25M.
Who are the investors of Aitia?
Investors of Aitia include Charles River Laboratories, Paycheck Protection Program, Merck Global Health Innovation Fund, Celgene, Alexandria Venture Investments and 12 more.
Who are Aitia's competitors?
Competitors of Aitia include Insilico Medicine, Healx, Unlearn, Cytocast, Cyclica and 7 more.
What products does Aitia offer?
Aitia's products include Gemini Digital Twin and 1 more.
Who are Aitia's customers?
Customers of Aitia include Pfizer, Mercks, AbbVie, Sanofi and Servier.
Loading...
Compare Aitia to Competitors
Standigm specializes in AI-driven drug discovery within the pharmaceutical industry. The company provides services, including target identification, lead generation, and optimization, as well as AI SaaS solutions for drug development. Standigm primarily serves sectors engaged in pharmaceutical research and drug development. It was founded in 2015 and is based in Seoul, South Korea.
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Healx is a technology company focused on artificial intelligence (AI) drug discovery for rare disease treatment within the pharmaceutical industry. The company specializes in using AI to identify drug-disease relationships and accelerate the development of new therapies for rare conditions. Healx's approach aims to increase the scale and success rate of rare disease treatment development by repurposing known compounds and running multiple drug discovery programs in parallel. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.
Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development. Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.
BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI foundation models to understand and predict biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
Loading...